Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — FY2015 Earnings Presentation

29 slides from Sucampo Pharmaceuticals's earnings presentation, Mar 8, 2016

  1. Slide 1: Fourth Quarter and Full Year 2015 Corporate Update and Financial Results

    The Science of innovation € $ suCAMPO Fourth Quarter and Full Year 2015 Corporate Update and Financial Results March 8, 2015

  2. Slide 2: Introductions and Forward-Looking Statements

    Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs

  3. Slide 3: Agenda

    Agenda $ sucampo_ Introductions and Forward-Looking Statements Corporate Update Pipeline Update Financial Update Closing Remarks Silvia Taylor Peter Greenleaf Peter Kiener, D. Phil Andrew Smith Peter Greenleaf

  4. Slide 4: Forward Looking Statement

    Forward Looking Statement $ sucampo This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to

  5. Slide 5: Q4 and FY15

    Q4 and FY15 Corporate Update Peter Greenleaf, Chairman and CEO

  6. Slide 6: Q4 and FY 15: Exceptional Results

    Q4 and FY 15: Exceptional Results 1. Delivered strong financials 2. Progressed and diversified our pipeline 3. Continue to transform and grow company through external

  7. Slide 7: Strong Financial Results

    Strong Financial Results $ sucampo REVENUE * Q4 overall revenue grew 47% to $55M + FY overall revenue grew 33% to $153M + Driven by continued strong performance of AMITIZA and inclusion of RTU results Excluding RTU related revenue, one-time milestone payment, co-promotion: — Q4 revenue grew 36% - FY

  8. Slide 8: U.S. AMITIZA Performance

    U.S. AMITIZA Performance $ sucampo Takeda AMITIZA net sales for royalty calc. purposes — Q4 grew 13% YoY to $102M — FY grew 15% to $380M AMITIZA prescriptions — Q4: ~390,000 TRx, increased 10% YoY -— 9% AMITIZA script growth outpacing 7.5% brand, generic market growth 9+ years of real-world experien

  9. Slide 9: Japan AMITIZA Performance

    Japan AMITIZA Performance $ sucampo Sucampo revenue — Q4 grew 74% to $13M — FY grew 64% to $49M + Includes one-time $5.0M milestone payment in Q4 triggered by Mylan’s annual net sales of AMITIZA exceeding ¥10B Volume-driven growth Retain current price for another 12-24 months Mylan remains focused o

  10. Slide 10: AMITIZA Rest of World

    AMITIZA Rest of World * Continued focus on expanding into new/emerging markets + Product continues strong growth and performance in U.S. and Japan + Project mid-to-high- single digit prescription groyyth

  11. Slide 11: Reaffirming 2016 Guidance

    Reaffirming 2016 Guidance $ sucampo + Total revenue: $195.0 million to $205.0 million + Adjusted net income: $45.0 million to $50.0 million + Adjusted EPS: $0.97 to $1.07 + Adjusted EBITDA: $100.0 million to $105.0 million — Guidance excludes amortization of acquired intangibles of approximately $17

  12. Slide 12: Pipeline Progress: Upcoming Milestones

    Pipeline Progress: Upcoming Milestones $ sucampo Timing Cobiprostone Top-line data from Phase 2 NERD/sGERD 1H16 (Rroi086) __ToPrline data from Phase 1 MAD tral qubbrosen e) Initiation of Phase 3 pivotal alternate formulation in adults (usm e) Top-line data from Phase 3 pivotal PFC (6-17 years) (ubme

  13. Slide 13: Acquired Innovative Product Candidates

    Acquired Innovative Product Candidates $ sucampo + Pipeline Diversification — CPP Exclusive Option + Exclusive option for Phase 3 program in familial adenomatous polyposis (FAP) — Orphan/rare disease space — Harnesses expertise in gastroenterology — Two VAP-1 inhibitor programs from RTU’s pipeline +

  14. Slide 14: Pipeline Update

    Pipeline Update Peter Kiener, D.Phil, CSO 14

  15. Slide 15: Product Pipeline Overview

    Product Pipeline Overview $ sucampo Development \A Filing proval Program Target First Indication pest NDA /MAA Fiing | Approval Gl/Metaboiic! Inflammation AMITIZA cic2 Pediatric functional constipation PS 2016 2017 Lubiprostone ES Pediatric functional constipation se 2018 (1), 2019 (1); Microparticl

  16. Slide 16: Lifecycle Management Programs for AMITIZA

    Lifecycle Management Programs for AMITIZA $ sucampo + Pediatric Functional Constipation (6-17 years) — Uses current formulation — Data expected 2H16 — Plan to file NDA 2H16 + Alternate Formulation — Initiate P3 study in adult patients with CIC 2H16 — Expect data 1H17 + Pediatric Functional Constipat

  17. Slide 17: AMITIZA Expansion Into New Markets

    AMITIZA Expansion Into New Markets $ sucamPo_ * Clinical trial applications have been filed, approved in Russia, Mexico and South Korea in CIC — Initiations of Phase 3 studies in 1H16 — First patient dosed in Russia

  18. Slide 18: Cobiprostone

    Cobiprostone $ SUCAMPO + NERD/sGERD — P2-study completed enrollment — Top-line data expected 1H16 + Oral Mucositis — P2 study ongoing — Top-line data expected 1H17 — Granted Fa:

  19. Slide 19: VAP-1 Inhibitor Programs

    VAP-1 Inhibitor Programs $ sucampo + VAP-1 inhibitors — Potential indications including NASH, COPD, diabetic macular edema and diabetic retinopathy, and modulation of tumor-specific immune responses — RTU-1096 * Top-line results expected from Phase 1 MAD 1H16 + Next step: generate additional preclin

  20. Slide 20: CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP

    CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset $ in FAP SUCAMPO + Significant opportunity — Phase 3 asset — Orphan indication for familial adenomatous polyposis (FAP) * Clinical development - Phase 3 ongoing — Enrollment expected to complete 1H16 — Phase 3 futility analysis 2H16 — Trial e

  21. Slide 21: Financial Update

    Financial Update Andrew Smith, CFO

  22. Slide 22: Q4 Total Revenues

    Q4 Total Revenues $ SUCAMPO 60 : “ 2O:28 37.8 Base mDecrease mincrease

  23. Slide 23: FY Total Revenues

    FY Total Revenues $ sucampo_ 180 2. = iar) 140 —00- 120 100 80 Py 40 20 é ft 2 ~ RJ é e € s we e Base sDecrease mincrease 2

  24. Slide 24: Q4 Adjusted EBITDA

    Q4 Adjusted EBITDA $ sucampo 35.0 30.0 25.0 20.0 15.0 10.0 18.9 27.7 Base we

  25. Slide 25: FY Adjusted EBITDA

    FY Adjusted EBITDA $ sucampo 80.0 ue ae 40: 600 oa = 50.0 40.0 + 30.0 20.0 + B7.5) 10.0 0.0 + +. o - * : . 2014 SCMPGross RTUGross SCMPR&D RTUR&D SCMPSM RTUG&A/SMG8AandOther 2015

  26. Slide 26: Strong Balance Sheet

    Strong Balance Sheet $ sucampo Item As of 12/31/15 As of 12/31/14 Cash, Cash $163.5M $53.5M $110.0M Equivalents, Restricted Cash and Investments Total Debt Net Debt As of 12/31/15 | As of 12/31/15 $252.4M $104.1M

  27. Slide 27: Reaffirming 2016 Guidance

    Reaffirming 2016 Guidance $ sucampo + Total revenue: $195.0 million to $205.0 million + Adjusted net income: $45.0 million to $50.0 million + Adjusted EPS: $0.97 to $1.07 + Adjusted EBITDA: $100.0 million to $105.0 million — Guidance excludes amortization of acquired intangibles of approximately $17

  28. Slide 28: Closing Remarks

    Closing Remarks Peter Greenleaf, Chairman and CEO 28

  29. Slide 29: 2016 Areas of Focus

    2016 Areas of Focus $ sucampo 1. Deliver outstanding financial performance: top and bottom-line growth 2. Advance pipeline programs 3. Evaluate additional opportunities for accelerated /sustainable mid-to- long- term gro\

Sucampo Pharmaceuticals — FY2015 Earnings Presentation on 6ix